Warning! GuruFocus detected
1 Severe warning sign
with KALV.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Compare
Compare
Traded in other countries / regions
KALV.USA4XC1.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2015-04-09Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 43.79 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.9 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year FCF Growth Rate | -15.5 | |||||
| 3-Year Book Growth Rate | -22.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.16 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.42 | |||||
| 9-Day RSI | 65.85 | |||||
| 14-Day RSI | 65.87 | |||||
| 3-1 Month Momentum % | 23 | |||||
| 6-1 Month Momentum % | 13.9 | |||||
| 12-1 Month Momentum % | -3.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.44 | |||||
| Quick Ratio | 10.44 | |||||
| Cash Ratio | 9.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 | |||||
| Shareholder Yield % | 0.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -117.7 | |||||
| ROA % | -89.15 | |||||
| ROIC % | -949.76 | |||||
| 3-Year ROIIC % | -322043.48 | |||||
| ROC (Joel Greenblatt) % | -2174.39 | |||||
| ROCE % | -103.77 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.12 | |||||
| Price-to-Tangible-Book | 4.12 | |||||
| EV-to-EBIT | -2.06 | |||||
| EV-to-EBITDA | -2.07 | |||||
| EV-to-Forward-Revenue | 17.14 | |||||
| EV-to-FCF | -2.82 | |||||
| Price-to-Net-Current-Asset-Value | 4.37 | |||||
| Price-to-Net-Cash | 4.88 | |||||
| Earnings Yield (Greenblatt) % | -48.54 | |||||
| FCF Yield % | -21.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KALV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
KalVista Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.77 | ||
| Beta | -0.16 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 48.71 | ||
| 14-Day RSI | 65.87 | ||
| 14-Day ATR ($) | 0.625308 | ||
| 20-Day SMA ($) | 11.89575 | ||
| 12-1 Month Momentum % | -3.19 | ||
| 52-Week Range ($) | 7.3 - 15.5 | ||
| Shares Outstanding (Mil) | 49.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
KalVista Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(KALV)'s stock price today?
The current price of KALV is $12.07. The 52 week high of KALV is $15.50 and 52 week low is $7.30.
When is next earnings date of KalVista Pharmaceuticals Inc(KALV)?
The next earnings date of KalVista Pharmaceuticals Inc(KALV) is 2025-07-11 Est..
Does KalVista Pharmaceuticals Inc(KALV) pay dividends? If so, how much?
KalVista Pharmaceuticals Inc(KALV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers